Differential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition

Abnormal activation of the mammalian target of rapamycin (mTOR) signaling pathway has been observed in a variety of human cancers. Therefore, targeting of the mTOR pathway is an attractive strategy for cancer treatment and several mTOR inhibitors, including AZD8055 (AZD), a novel dual mTORC1/2 inhibitor, are currently in clinical trials. Although bone marrow (BM) suppression is one of the primary side effects of anticancer drugs, it is not known if pharmacological inhibition of dual mTORC1/2 affects BM hematopoietic stem and progenitor cells (HSPCs) function and plasticity. Here we report that dual inhibition of mTORC1/2 by AZD or its analogue (KU-63794) depletes mouse BM Lin−Sca-1+c-Kit+ cells in cultures via the induction of apoptotic cell death. Subsequent colony-forming unit (CFU) assays revealed that inhibition of mTORC1/2 suppresses the clonogenic function of hematopoietic progenitor cells (HPCs) in a dose-dependent manner. Surprisingly, we found that dual inhibition of mTORC1/2 markedly inhibits the growth of day-14 cobblestone area-forming cells (CAFCs) but enhances the generation of day-35 CAFCs. Given the fact that day-14 and day-35 CAFCs are functional surrogates of HPCs and hematopoietic stem cells (HSCs), respectively, these results suggest that dual inhibition of mTORC1/2 may have distinct effects on HPCs versus HSCs.

[1]  A. Larue,et al.  Catalase inhibits ionizing radiation-induced apoptosis in hematopoietic stem and progenitor cells. , 2015, Stem cells and development.

[2]  A. Hirao,et al.  Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis. , 2014, Journal of biochemistry.

[3]  C. Schnell,et al.  Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT , 2014, Clinical Cancer Research.

[4]  Daohong Zhou,et al.  Rapamycin Enhances Long-Term Hematopoietic Reconstitution of Ex Vivo Expanded Mouse Hematopoietic Stem Cells by Inhibiting Senescence , 2014, Transplantation.

[5]  Yi Zheng,et al.  Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis , 2013, Haematologica.

[6]  D. Sabatini,et al.  mTORC1 Phosphorylation Sites Encode Their Sensitivity to Starvation and Rapamycin , 2013, Science.

[7]  R. Coleman,et al.  The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer , 2012, Clinical Cancer Research.

[8]  P. S. Klein,et al.  Maintenance of Hematopoietic Stem Cells through Regulation of Wnt and mTOR Pathways , 2012, Nature Medicine.

[9]  S. Armstrong,et al.  mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. , 2012, Cell stem cell.

[10]  Jeffrey A. Magee,et al.  Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. , 2012, Cell stem cell.

[11]  E. Raymond,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma , 2012, British Journal of Cancer.

[12]  J. Tamburini,et al.  The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.

[13]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[14]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Hall,et al.  Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.

[16]  Ivan Babic,et al.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.

[17]  L. Rimsza,et al.  Developmental differences in megakaryocytopoiesis are associated with up-regulated TPO signaling through mTOR and elevated GATA-1 levels in neonatal megakaryocytes. , 2011, Blood.

[18]  Daohong Zhou,et al.  Inhibition of p38 mitogen-activated protein kinase promotes ex vivo hematopoietic stem cell expansion. , 2011, Stem cells and development.

[19]  C. García-echeverría.  Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. , 2010, Bioorganic & medicinal chemistry letters.

[20]  M. Milella,et al.  The mTOR pathway: a new target in cancer therapy. , 2010, Current cancer drug targets.

[21]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[22]  M. Carroll,et al.  A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia , 2009, Clinical Cancer Research.

[23]  L. Chin,et al.  High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.

[24]  C. Chresta,et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.

[25]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[26]  E. Vellenga,et al.  Mammalian Target of Rapamycin Is Required for Thrombopoietin‐Induced Proliferation of Megakaryocyte Progenitors , 2006, Stem cells.

[27]  Yong Wang,et al.  Total body irradiation selectively induces murine hematopoietic stem cell senescence. , 2006, Blood.

[28]  G. Laurent,et al.  Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.

[29]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[30]  R. Loewith,et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.